SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Lignende værker

• Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
  af: Fadini, Gian Paolo, et al.
  Udgivet: (2019)
• Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
  af: Bonora, Benedetta Maria, et al.
  Udgivet: (2020)
• Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
  af: Bonora, Benedetta Maria, et al.
  Udgivet: (2019)
• Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
  af: Fadini, Gian Paolo, et al.
  Udgivet: (2018)
• Managing diabetes in diabetic patients with COVID: where do we start from?
  af: Avogaro, Angelo, et al.
  Udgivet: (2021)